Potential molecular prognostic markers in head and neck squamous cell carcinomas

Head and Neck

Volumn 23, Issue 2, 2001, Pages 147-159

  Quon, H ^a,b,c   Liu, F F ^a,b   Cummings, B J ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Department of Radiation Oncology   (Canada)

Author keywords

Cyclin D1; EGFR; Head neck squamous cell carcinomas; p53; Prognostic factors; TGF

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; TRANSFORMING GROWTH FACTOR ALPHA;

CANCER RADIOTHERAPY; CANCER SURGERY; HEAD AND NECK CARCINOMA; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; GENETIC MARKERS; HEAD AND NECK NEOPLASMS; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035176636     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#     Document Type: Review

References (110)

1. Tumors of the larynx and hypopharynx
2. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial
3. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy
4. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer
5. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck
6. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: A randomized phase III study
7. TP53 mutation is an independent prognostic marker for poor outcome of radiotherapy in squamous cell carcinoma of the head and neck
8. Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study
9. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
10. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma
11. Predicting the response of head and neck cancers to radiation therapy with a multivariate modelling system: An analysis of the RTOG head and neck registry
12. T1/T2 glottic cancer managed by external beam radiotherapy: The influence of pretreatment hemoglobin on local control
13. Primary radiotherapy of larynx and pharynx carcinoma - An analysis of some factors influencing local control and survival
14. Primary radiotherapy of carcinoma of the supraglottic larynx - A multivariate analysis of prognostic factors
15. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma
16. The EORTC randomized trial on three fractions per day and misonidazole in advanced head and neck cancer: Prognostic factors
17. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
18. Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers: Results of RTOG 91-08
19. Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 GY in 7 weeks
20. Primary radiotherapy of squamous cell carcinoma of the oropharynx and pharyngolarynx: Tentative multivariate modelling system to predict the radiocurability of neck nodes
21. The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: Results of an analysis from the RTOG head and neck database
22. Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer?
23. Treatment duration as a prognostic factor for local control and survival in epidermoid carcinomas of the tonsillar region treated by combined external beam irradiation and brachytherapy
24. A multivariate primary tumour control analysis in 465 patients treated by radical radiotherapy for cancer of the tonsillar region: Clinical and treatment parameters as prognostic factors
25. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma
26. Prognostic value of tumor regression during radiotherapy for head and neck cancer: A prospective study
27. Prognosis in mouth cancer: Tumour factors
28. Implications of tumour in resection margins following surgical treatment of squamous cell carcinoma of the head and neck
29. Advanced carcinoma of the larynx: Results of surgery and radiotherapy without induction chemotherapy (1980-1985): A multivariate analysis
30. Mechanisms of p53-mediated apoptosis
31. The role of p53 tumor suppressor gene in human head and neck tumorigenesis
32. p53 overexpression in head and neck squamous cell carcinoma: Review of the literature
33. The tumour suppressor gene p53
34. p53, the cellular gatekeeper for growth and division
35. The cellular response to p53: The decision between life and death
36. The p53 gene as a modifier of intrinsic radiosensitivity: Implications for radiotherapy
37. Review article: The role of oncogenes, tumour suppressor genes and growth factors in oral squamous cell carcinoma: A case of apoptosis versus proliferation
38. p53, guardian of the genome
39. Apoptosis in cancer therapy: Crossing the threshold
40. Clinical implications of p53: Effect on prognosis, tumor progression and chemotherapy response
41. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: Correlation with p53 gene alterations
42. Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations
43. Discordance of p53 status in matched primary tumours and metastases in head and neck squamous ceil carcinoma patients
44. Comparison of p53 immunoreactivity in fresh-cut versus stored slides with and without microwave heating
45. Problems with p53 immunohistochemical staining: The effect of fixation and variation in the methods of evaluation
46. Retrieval of p53 protein in paraffin-embedded head and neck tumor tissues
47. Patterns of p53 gene mutations in head and neck cancer: Fullqength gene sequencing and results of primary radiotherapy
48. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers
49. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy
50. Is p53 an independent prognostic factor in patients with laryngeal carcinoma?
51. Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy
52. Radioresistance and p53 status of T2 laryngeal carcinoma: Analysis by immunohistochemistry and denaturing gradient gel electrophoresis
53. p53 overexpression in head and neck carcinoma and radiotherapy results
54. p53 status of head and neck cancer: Relation to biological characteristics and outcome of radiotherapy
55. The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma
56. Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma
57. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck
58. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma
59. p53 expressions: Predicting recurrence and second primary tumors in head and neck squamous cell carcinoma
60. Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications
61. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx
62. The receptor for EGF and its ligands: Expression, prognostic value and target for therapy in cancer
63. Growth factors and intracetlular signaling
64. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy
65. Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy
66. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer
67. TGF-alpha and EGFR in head and neck cancer
68. Oncogenes in head and neck cancer
69. EGF receptor expression in primary laryngeal cancer: Correlation with clinico-pathological features and prognostic significance
70. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer
71. Quantitative immunohistochemical analysis of transforming growth factor- alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
72. Cell proliferation and cell death
73. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression
74. PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas
75. Dysregulated cyclin D1 expression early in head and neck tumorigenesis: In vivo evidence for an association with subsequent gene amplification
76. Multiple genetic lesions in laryngeal squamous cell carcinomas
77. Chromosome 11q13 amplification in head and neck squamous cell carcinoma
78. Molecular and immunohistochemical analysis of the bcl-1/cyclin D1 gene in laryngeal squamous cell carcinomas: Correlation of protein expression with lymph node metastases and advanced clinical stage
79. Cyclin D1 overexpression in primary hypopharyngeal carcinomas
80. Cyclin D1 expression as a prognostic factor in advanced hypopharyngeal carcinoma
81. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue
82. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: Prognostic significance and clinical implications
83. Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma
84. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma
85. Role of the p16 tumor suppressor gene in cancer
86. Has the cellular proliferation marker Ki67 any clinical relevance in squamous cell carcinoma of the head and neck?
87. Bcl-2 family proteins
88. bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy
89. Prognostic significance of Bcl-2 expression in localized squamous cell carcinoma of the head and neck
90. Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy
91. p53 mutations increase resistance to ionizing radiation
92. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck
93. Norrealization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line
94. Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology
95. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
96. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy
97. Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy
98. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro
99. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma
100. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers
101. Systemic p53 gene therapy in combination with radiation results in human tumor regression
102. Therapeutic application of antigrowth factor receptor antibodies
103. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines
104. Phase I trial of chimerized anti-epidermal growth factor (anti-EGFr) antibody in combination with either once-daily or twicedaily irradiation for locally advanced head and neck malignancies
105. A phase I study of chimerized anti-epidermal growth factor receptor (EGFf) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC)
106. Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,744 in patients with advanced solid tumors
107. Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358, 774: A phase I and pharmacokinetic (PK) study
108. Expression profiling using cDNA microarrays
109. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma